ALEC Alector, Inc.
$2.10▲ +14.75%
Healthcare
Other
After hours
$2.07▼ -1.43%
Oct 27, 4:46 PM ET
Volume 4.57M
Avg Volume (10D) 2.42M
Key Metrics & Fundamentals
Market Cap
$234.48M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.09 - 2.76
% vs 50 MA
0.64%
% vs 200 MA
3.67%
RSI-14
57.3
MACD Histogram
+0.0100
Beta (1Y vs SPY)
1.59
Free Cash Flow
-$34.25M
Gross Rev
$3.32M
Gross Profit
$3.32M
EBITDA
-$22.34M
COGS
–
Operating Exp
$27.71M
Operating Income
-$24.39M
EBIT
-$24.39M
Pretax Income
-$22.86M
Net Income
-$22.99M
EPS (Diluted)
-0.21
Price & Volume History
Loading chart…
Recent News
Alector stock surges 13% on premium-priced equity offering
Investing.com · Oct 16, 2026 9:26 AM ET
Update: Alector Prices $75 Million Stock Offering
MT Newswires · Oct 16, 2026 8:09 AM ET
Alector Prices $75 Million Stock Offering
MT Newswires · Oct 16, 2026 7:45 AM ET
Alector Announces Pricing of Underwritten Offering
GlobeNewswire · Oct 16, 2026 7:30 AM ET
Alector (ALEC) Stock Fair Value Rises After Genentech Deal Draws Split Analyst Views
Simply Wall St. · Oct 15, 2026 8:21 PM ET
Alector Maps Brain-Delivery Pipeline for Alzheimer’s, Parkinson’s Therapies
MarketBeat · Oct 13, 2026 3:02 PM ET
Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
Stocktwits · Oct 9, 2026 9:12 PM ET
Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline
GlobeNewswire · Oct 7, 2026 4:05 PM ET
Roche Stocks: Genentech Commits $100 Million Upfront in Potential $1.27 Billion Parkinson's Deal
GuruFocus.com · Oct 6, 2026 3:43 PM ET
Alector shares up after sealing $1.27bn Roche Parkinson’s disease license deal
Pharmaceutical Technology · Oct 6, 2026 6:59 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See ALEC's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.